Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc (GSK) covers the month of July 2019, with a specific reporting date of July 15, 2019. The document serves as a transaction notification regarding share dealings by Persons Discharging Managerial Responsibilities (PDMRs) and persons closely associated with them.
Key Financial Metrics
The filing does not contain company-wide financial performance data such as revenue, profit, cash flow, margins, debt, or liquidity. It exclusively details specific share transaction volumes and prices for individual executives.
| Instrument | Transaction Price | Total Volume (Shares/ADS) | Exchange |
|---|---|---|---|
| Ordinary Shares (GBP) | £16.3240 | 4,080,000 | London Stock Exchange |
| American Depositary Shares (USD) | $40.9300 | 485,000 | New York Stock Exchange |
Material Changes
No material changes to the company's financial position or operations are reported in this filing. The document records routine increases in notional share interests for executives resulting from the re-investment of dividends paid on July 11, 2019, under the Company's Deferred Annual Bonus Plan.
Guidance, Outlook, and Risks
The filing contains no management commentary, forward-looking guidance, risk factors, or contingencies. It is a regulatory disclosure of specific insider transactions executed on July 12, 2019.
Investor Verification Checklist
- Verify that the reported transactions were executed via the Deferred Annual Bonus Plan and not through open market purchases.
- Confirm the dividend payment date of July 11, 2019, aligns with the company's standard dividend schedule.
- Check the aggregate volume of Ordinary Shares (4,080,000) and ADS (485,000) against the total number of PDMRs to ensure all required disclosures are present.
- Validate the transaction prices (£16.3240 and $40.9300) against the market closing prices for July 12, 2019.